Liposomes and Drug Delivery

Pharmaceutical Manufacturing Handbook: Production and Processes

Volumn , Issue , 2007, Pages 443-533

  Antimisiaris, Sophia G ^a   Kallinteri, Paraskevi ^b   Fatouros, Dimitrios G ^c  

^a UNIVERSITY OF PATRAS   (Greece)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Liposomes and drug delivery; PEGylated liposomal doxorubicin; Therapeutic liposomes

Indexed keywords

EID: 84889774094     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470259818.ch13     Document Type: Chapter

References (462)

1. Bangham, A. D., Standish, M. M., and Watkins, J. C. (1965), Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13, 238-252.
2. Papahadjopoulos, D. (1978), Liposomes and their uses in biology and medicine, Ann. N.Y. Acad. Sci., 408, 1.
3. Gregoriadis, G. (1978), Liposomes in therapeutic and preventive medicine:The development of the drug-carrier concept, Ann. N.Y. Acad. Sci., 308, 343-370.
4. Kirby, C., Clarke, J., and Gregoriadis, G. (1980), Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum, FEBS Lett., 111, 324-328.
5. Pain, D., Das, P. K., Ghosh, P. C., and Bachhawat, B. K. (1984), Increased circulatory half-life of liposomes after conjugation with dextran, J. Biosci., 6, 811-816.
6. Allen, T. M., and Chonn, A. (1987), Large unilamellar liposomes with low uptake into the reticuloendothelial system, FEBS Lett., 223, 42-46.
7. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., et al, (1991), Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA, 88,11460-11464.
8. Lasic, D. D., Martin, F. J., Gabizon, A., Huang, S. K., and Papahadjopoulos, D. (1991), Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times, Biochim. Biophys. Acta, 1070, 187-192.
9. Torchilin, V. P., Levchenko, T. S., Whiteman, K. R., Yaroslavov, A. A., Tsatsakis, A. M., Rizos, A. K., et al. (2001), Amphiphilic poly-N-vinylpyrrolidones: Synthesis, properties and liposome surface modification, Biomaterials, 22, 3035-3044.
10. Takeuchi, H., Kojima, H., Yamamoto, H., and Kawashima, Y. (2001), Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats, J. Controlled Release, 75, 83-91.
11. Haran, G., Cohen, R., Bar, L., and Barenholz, Y. (1993), Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathis weak bases, Biochim. Biophys. Acta, 1151, 201-215.
12. Loan Honeywell-Nguyen, P., Wouter, H. W., Groenink, A., de Graaff, M., and Bouwstra, J. A. (2003), The in vivo transport of elastic vesicles into human skin: Effects of occlusion, volume and duration of application, J. Controlled Release, 90, 243-255.
13. Lasic, D. (1993), Liposomes from Physics to Applications, Elsevier, London.
14. Hauser, H. (2000), Short-chain phospholipids as detergents, Biochim. Biophys. Acta, 1508, 164-181.
15. Eibl, H. (1980), Synthesis of glycerophospholipids, Chem. Phys. Lipids, 26, 405-429.
16. Barenholz, Y.,Thompson,T. E. (1999), Sphingomyelin: Biophysical aspects, Chem. Phys. Lipids, 102, 29-34.
17. Barenholz, Y. (2004), Sphingomyelin and cholesterol: From membrane biophysics and rafts to potential medical applications, Subcell. Biochem., 37, 167-215.
18. Patel, G. B., and Sprott, G. D. (1999), Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems, Crit. Rev. Biotechnol., 19, 317-357.
19. Fatouros, D., Ioannou, P. V., and Antimisiaris, S. G. (2006), Novel nanosized arsenic containing vesicles for drug delivery: Arsonoliposomes, J. Nanosci. Nanotechnol., 6, 2618-2687.
20. Biltonen, R. L., and Lichtenberg, D. (1993), The use of differential scanning calorimetry as a tool to characterize liposome preparations, Chem. Phys. Lipids, 64, 129-142.
21. Champan, D., Urbina, J., and Keough, K. M. (1974), Studies of lipid water systems using differential scanning calorimetry, J. Biol. Chem., 249 (8), 2512-2521.
22. van Osdol, W. W., Johnson, M. L., Ye, Q., and Biltonen M. (1991), Relaxation dynamics of the gel to liquid-crystalline transition of phosphatidylcholine bilayers. Effects of chain length and vesicle size, Biophys. J., 59, 775-785.
23. van Osdol, W. W., Ye, Q., Johnson, M. L., and Biltonen, M. (1992), Effects of the anesthetic dibucaine on the kinetics of the gel-liquid crystalline transition of dipalmitoylphos-phatidylcholine multilamellar vesicles, Biophys. J., 63, 1011-1017.
24. Momo, F., Fabris, S., Bindoli, A., Scutari, G., and Stevanato, R. (2002), Different effects of propofol and nitrosopropofol on DMPC multilamellar liposomes, Biophys. Chem., 95, 145-155.
25. Zhang, F., and Rowe, E. S. (1994), Calorimetric studies of the interactions of cytochrome c with dioleoylphosphatidylglycerol extruded vesicles: Ionic strength effects, Biochim. Biophys. Acta, 1193, 219-225.
26. Lo, Y. L., and Rahman, Y. E. (1995), Protein location in liposomes, a drug carrier: A prediction by differential scanning calorimetry, J. Pharm. Sci., 84, 805-814.
27. Parente, R. A., and Lentz, B. R. (1985), Advantages and limitations of 1-palmitoyl-2-[[2-[4-(6-phenyl-trans-1,3,5-hexatrienyl)phenyl]ethyl]carbonyl]-3-sn-phosphatidylcholine as a fluorescent membrane probe, Biochemistry, 24, 6178-6185.
28. Metso, A. J., Zhao, H., Tuunainen, I., and Kinnnunen, P. K. (2004), Characterization of the main transition of dinervonoylphosphocholine liposomes by fluorescence spectros-copy, Biochim. Biophys. Acta, 1663, 222-231.
29. van Langen, H., Van Ginkel, G., Shaw, D., and Levine, Y. K. (1989), The fidelity of response by 1-[4-(trimethylammonio)phenyl]-6-phenyl-1,3,5-hexatriene in time-resolved fluorescence anisotropy measurements on lipid vesicles. Effects of unsaturation, head-group and cholesterol on orientational order and reorientational dynamics, Eur. Biophys. J., 17, 37-48.
30. Davenport, L., and Targowski, P. (1996), Submicrosecond phospholipid dynamics using a long-lived fluorescence emission anisotropy probe, Biophys. J., 71,1837-1852.
31. de Kruijff, B., and Cullis, P. R. (1980), The influence of poly(L-lysine) on phospholipid polymorphism. Evidence that electrostatic polypeptide- phospholipid interactions can modulate bilayer/non-bilayer transitions, Biochim. Biophys. Acta, 601, 235-240.
32. Vasilenko, I., de Kruijff, B., and Verkleij, A. J. (1982), The synthesis and use of thion-phospholipids in 31P-NRM studies of lipid polymorphism, Biochim. Biophys. Acta, 685, 144-152.
33. Perkins, W. R., Mincey, S. R., Ostro, M. J., Taraschi, T. F., and Janoff, A. S. (1988), The captured volume of multilamellar vesicles, Biochim. Biophys. Acta, 943, 103-107.
34. Davis, J. H. (1983),The description of membrane lipid conformation, order and dynamics by 2H-NMR, Biochim. Biophys. Acta, 737, 117-171.
35. Wu, W. G., Dowd, S. R., Simplaceanu, V., Peng, Z. Y., and Ho, C. (1985), 19F NMR investigation of molecular motion and packing in sonicated phospholipid vesicles, Biochemistry, 24, 7153-7161.
36. Bertoli, E., Masserini, M., Sonnino, S., Ghidoni, R., Cestaro, B., and Tettamanti, G. (1981), Electron paramagnetic resonance studies on the fluidity and surface dynamics of egg phosphatidylcholine vesicles containing gangliosides, Biochim. Biophys. Acta, 647, 196-202.
37. Shin, Y. K., and Freed, J. H. (1989), Dynamic imaging of lateral diffusion by electron spin resonance and study of rotational dynamics in model membranes. Effect of cholesterol, Biophys. J., 55, 537-550.
38. Lai, C. S., Joseph, J., and Shih, C. C. (1989), Molecular dynamics of antitumor ether-linked phospholipids in model membranes: A spin-label study, Biochem. Biophys. Res. Commun., 160, 1189-1195.
39. Ondrias, K., Stasko, A., Marko, V., and Nosal, R. (1989), Influence of beta-adrenoceptor blocking drugs on lipid-protein interaction in synaptosomal membranes. An ESR study, Chem. Biol. Interact., 69, 87-97.
40. Hoekstra, D. (1982), Fluorescence method for measuring the kinetics of Ca2+-induced phase separations in phosphatidylserine- containing lipid vesicles, Biochemistry, 21, 1055-1061.
41. Hoekstra, D. (1990), Fluorescence assays to monitor membrane fusion: Potential application in biliary lipid secretion and vesicle interactions, Hepatology, 12, 61S-6S.
42. LeNeveu, D. M.,Rand,R. P.,Parsegian,V.A., and Gingel,D. (1976), Apparent modification of forces between lecithin bilayers, Science, 191, 399-400.
43. Franks, N. P. (1976), Structural analysis of hydrated egg lecithin and cholesterol bilayers. I. X-ray diffraction, J. Mol. Biol., 100, 345-358.
44. Worcester, D. L., and Franks, N. P. (1976), Structural analysis of hydrated egg lecithin and cholesterol bilayers. II. Neutron diffraction, J. Mol. Biol., 100, 359-378.
45. LeNeveu, D. M., and Rand, R. P. (1977), Measurement and modification of forces between lecithin bilayers, Biophys. J., 18, 209-230.
46. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchillin, V. P., et al. (1998), Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA, 95, 4607-4612.
47. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., and Papahadjopoulos, D. (1999), Optimizing liposomes for delivery of chemotherapeutic agents to solid tumour, Pharmacol. Rev., 51, 691-743.
48. Devine, D. V., Wong, K., Serrano, K., Chonn A., and Cullis, P. R. (1994), Liposome-complement interactions in rat serum: Implications for liposome survival studies, Biochim. Biophys. Acta, 1191, 43-51.
49. Kolchens, S., Ramaswami, V., Birgenheier, J., Nett, L., and O'Brien, D. F. (1993), Quasi-elastic light scattering determination of the size distribution of extruded vesicles, Chem. Phys. Lipids, 65, 1-10.
50. Lesieur, S., Grabielle-Madelmont, C., Paternostre, M. T., and Ollivon, M. (1991), Size analysis and stability study of lipid vesicles by high- performance gel exclusion chromatography, turbidity, and dynamic light scattering, Anal. Biochem., 1, 192, 334-343.
51. Matsuzaki, K., Murase, O., Sugishita, K., Yoneyama, S., Akada, K., Ueha, M., Nakamura, A., and Kobayashi, S. (2000), Optical characterization of liposomes by right angle light scattering and turbidity measurement, Biochim. Biophys. Acta, 31, 219-226.
52. Moon, M. H., and Giddings, J. C. (1993), Size distribution of liposomes by flow field-flow fractionation, J. Pharm. Biomed. Anal., 11, 911-920.
53. Korgel, B. A., van Zanten, J. H., and Monbouquette, H. G. (1998), Vesicle size distributions measured by flow field-flow fractionation coupled with multiangle light scattering, Biophys. J., 74, 3264-3272.
54. Lee, H., Williams, S. K., Allison, S. D., and Anchordoquy, T. J. (2001), Analysis of self-assembled cationic lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering, Anal. Chem., 73, 837-843.
55. Grabielle-Madelmont, C., Lesieur, S., and Ollivon, M. (2003), Characterization of loaded liposomes by size exclusion chromatography, J. Biochem. Biophys. Methods, 56, 189-217.
56. Goni, F. M., and Alonso, A. (2000), Spectroscopic techniques in the study of membrane solubilization, reconstitution and permeabilization by detergents, Biochim. Biophys. Acta, 1508, 51-68.
57. Alonso,A., Villena,A., and Goni,F. M. (1981), Lysis and reassembly of sonicated lecithin vesicles in the presence of Triton X-100, FEBS Lett., 123, 200-204.
58. Kokona, M., Kallinteri, P., Fatouros, D., and Antimisiaris, S. G. (2000), Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: Effect of lipid composition, Eur. J. Pharm. Sci., 9, 245-252.
59. Almog, S., Litman, B. J., Wimley, W., Cohen, J., Wachtel, E. J., Barenholz, Y., Ben-Saul, A., and Lichtenberg, D. (1990), States of aggregation and phase transformations in mixtures of phosphatidylcholine and octyl glucoside, Biochemistry, 29, 4582-4592.
60. Lopez, O., de la Maza, A., Coderch, L., Lopez-Iglesias, C., Wehrli E., and Parra, J. L. (1998), Direct formation of mixed micelles in the solubilization of phospholipid liposomes by Triton X-100, FEBS Lett., 426, 314-318.
61. Fatouros, D. G., Piperoudi, S., Gortzi, O., Ioannou, P. V., and Antimisiaris, S. G. (2005), Physical stability of sonicated arsonoliposomes: Effect of calcium ions, J. Pharm. Sci. US, 94, 46-55.
62. Akashi, K., Miyata, H., Itoh. H., and Kinoshita, K., Jr. (1996), Preparation of giant lipo-somes in physiological conditions and their characterization under an optical microscope, Biophys. J., 71, 3242-3250.
63. Shohda, K., Toyota, T., Yomo, T., and Saguwara, T. (2003), Direct visualization of DNA duplex formation on the surface of a giant liposome, Chembiochem., 4,778-781.
64. Henriksen, J. R., and Ipsen, J. H. (2004), Measurement of membrane elasticity by micro-pipette aspiration, Eur. Phys. J. E. Soft Matter, 14,149-167.
65. Olson, F., Hunt, C. A., Szoka, F. C., Vail, W. J., and Papahadjopoulos, D. (1979), Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, Biochim. Biophys. Acta, 557, 9-23.
66. Weibull, C., Christiansson, A., and Carlemalm, E. (1983), Extraction of membrane lipids during fixation, dehydration and embedding of Acholeplasma laidlawii-cells for electron microscopy, J. Microsc., 129, 201-207.
67. Dermer, G. B. (1968), An autoradiographic and biochemical study of oleic acid absorption by intestinal slices including determinations of lipid loss during preparation of electron microscopy, J. Ultrastruct. Res., 22, 312-325.
68. Hope, M. J., Walker, D. C., and Cullis, P. R. (1983), Ca2+ and pH induced fusion of small unilamellar vesicles consisting of phosphatidylethanolamine and negatively charged phospholipids: A freeze fracture study, Biochem. Biophys. Res. Commun., 110, 15-22.
69. Hope, M. J., Wong, K. F., and Cullis, P. R. (1989), Freeze-fracture of lipids and model membrane systems, J. Electron. Microsc. Tech., 13, 277-287.
70. Burger, K. N., Nieva, J. L., Alonso, A., and Verkleij, A. J. (1991), Phospholipase C activity- i nduced fusion of pure lipid model membranes. A freeze fracture study, Biochim. Biophys. Acta, 1068, 249-253.
71. Meyer, H. W., and Richter, W. (2001), Freeze-fracture studies on lipids and membranes, Micron., 32, 615-644.
72. Taggar, A. S., Alnajim, J., Anantha, M., Thomas, A., Webb, M., Ramsay, E., and Bally, M. B. (2006), Copper- topotecan complexation mediates drug accumulation into lipo-somes, J. Controlled Release, 114, 78-88.
73. Anabousi, S., Laue, M., Lehr, C. M., Bakowsky, U., and Ehrhardt. C. (2005), Assessing transferring modification of liposomes by atomic force microscopy and tramsmission electron microscopy, Eur. J. Pharm. Biopharm, 60, 295-303.
74. Bellare, J. R., Davis, H. T., Scriven, L. E., and Talmon, Y. (1988), Controlled environment vitrification system. An improved sample preparation technique, J. Elec. Micr. Tech., 10, 87-111.
75. Dubochet, J., Adrian, M., Chang, J., Homo, J. C., Lepault, J., McDowell, A. W., and Schultz, P. (1988), Cryo-electron microscopy of vitrified specimens, Q. Rev. Biophys., 21, 129-228.
76. Frederik, P. M., Stuart, M. C., and Verklej, A. J. (1989), Intermediary structures during membrane fusion as observed by cryo- electron microscopy, Biochim. Biophys. Acta, 979, 275-278.
77. Siegel, D. P., Green, W., and Talmon, J. (1989), Intermediates in membrane fusion and bilayer/nonbilayer phase transitions imaged by time- resolved cryo-transmission electron microscopy, Biophys J., 56, 161-169.
78. Frederik, P. M., Burger, K. N., Stuart, M. C., and Verklej, A. J. (1991), Lipid polymorphism as observed by cryo- electron microscopy, Biochim. Biophys. Acta, 1062, 133-141.
79. Siegel, D. P., Green, W., and Talmon, J. (1994), The mechanism of lamellar-to-inverted hexagonal phase transitions: A study using temperature-jump cryo-electron microscopy, Biophys. J., 66, 402-414.
80. Mozafari, M. R., Reed, C. J., Rostron, C., and Hasirci, V. (2005), A review of scanning probe microscopy investigations of liposome- DNA complexes, J. Liposome Res., 15, 93-107.
81. Papadimitriou, E., and Antimisiaris, S. G. (2000), Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro, J. Drug Target., 5, 335-351.
82. Haywood, A. M., and Boyer, B. P. (1986), Ficoll and dextran enhance adhesion of Sendai virus to liposomes containing receptor (ganglioside GD1a), Biochemistry, 25, 3925-3929.
83. Shichijo, S., and Alving, C. R. (1986), Inhibitory effects of gangliosides on immune reactions of antibodies to neutral glycolipids in liposomes, Biochim. Biophys. Acta, 858, 118-124.
84. Ho, R. J., Rouse, B.T., and Huang, L. (1986),Target-sensitive immunoliposomes: Preparation and characterization, Biochemistry, 25, 5500-5506.
85. Bogdanov, A. A., Gordeeva, L. V., Torchilin, V. P., and Margolis, L. B. (1989), Lectin-bearing liposomes: Differential binding to normal and to transformed mouse fibroblasts, Exp. Cell Res., 181, 362-374.
86. Woodle, M. C., and Lasic, D. D. (1992), Sterically stabilized liposomes, Biochim. Biophys. Acta, 1113, 171-199.
87. Woodle, M. C., Collins, L. R., Sponsler, E., Kossovsky, N., Papahadjopoulos, D., and Martin, F. J. (1992), Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential, Biophys. J., 61, 902-910.
88. Mayhew, E., Lazo, R., and Vail, W. J. (1989), Preparation of liposomes entrapping cancer chemotherapeutic agents for experimental in vivo and in vitro studies, in Gregoriadis, G., Ed., Liposome Technology, Vol. II, CRC Press, Boca Raton, FL, Chapter 2.
89. Fatouros, D. G., and Antimisiaris, S. G. (2001), Physicochemical properties of liposomes incorporating hydrochlorothiazide and chlorothiazide, J. Drug Target., 9, 61-74.
90. Fatouros, D. G., and Antimisiaris, S. G. (2002), Effect of amphiphilic drugs on the stability and zeta-potential of their liposome formulations: A study with prednisolone, diazepam and griseofulvin, J. Coll. Interf. Sci., 251, 271-277.
91. Szoka, F. C., and Papahadjopoulos, D. (1980), Comparative properties and methods of preparation of lipid vesicles (liposomes), Ann. Rev. Biophys. Bioeng., 75, 4194-4199.
92. Kulkarni, S. B., Betageri, G. V., and Singh, M. (1995), Factors affecting microencapsula-tion of drugs in liposomes, J. Microencapsul., 12, 229-246.
93. Amselem, S., Gabizon, A., and Barenholz, Y. (1990), Optimization and up scaling of doxorubicin-containing liposomes for clinical use, J. Pharm. Sci., 79,1045-1052.
94. Mezei, M., and Nugent, F. J. (1984), Method of encapsulating biologically active materials in multilmellar lipid vesicles, U.S. Patent 4, 485,054.
95. Ma, L., Ramachandran, C., and Weiner, N. D. (1991), Partitioning of a homologous series of alkyl p-amino benzoates in dipalmitoyl phosphatidyl choline liposomes: Effect of liposomes type, Int. J. Pharm., 70, 209-218.
96. Betageri, G. V., and Parsons, D. L. (1992), Drug encapsulation and release from multila-mellar and unilamellar liposomes, Int. J. Pharm., 81, 235-241.
97. Puglisi, G., Fresta, M., La Rosa, C., Ventura, C. A., Panic, A. M., and Mazzonne,A. (1992), Liposomes as potential drug carrier for citicoline (CDP-choline) and the effect of formulation conditions on encapsulation efficiency, Pharmazie, 47, 211-215.
98. Betageri, G. V. (1993), Liposomal encapsulation and stability of dideoxynosine triphos-phate, Drug Dev. Ind. Pharm., 19, 531-539.
99. Fresta, M., Villari, A., Puglisi, G., and Cavallaro, G. (1993), 5-Fluorouracil: Various kinds of loaded liposomes: Encapsulation efficiency, storage stability and fusogenic properties, Int. J. Pharm., 99, 145-156.
100. Elorza, B., Elorza, M. A., Frutos, G., and Chantres, J. R. (1993), Characterization of 5-flourouracil loaded liposomes prepared by reverse phases evaporation or freezing thawing extrusion methods: Study of release, Biochim. Biophys. Acta, 1153, 135-142.
101. Law, S. L., Chang, P., and Lin, C. H. (1991), Characteristics of mitoxantrone loading on liposomes, Int. J. Pharm., 70, 1-7.
102. Alpar, O. H., Bamford, J. B., and Walters, V. (1981), In vitro incorporation and release of hydroxycobalamin by liposomes, Int. J. Pharm., 7, 349-351.
103. Crommelin, D. J. A., and Van Bloois, L. (1983), Preparation and characterization of doxorubicin containing liposomes. Part 2. Loading capacity, long-term stability and doxorubicin bilayer interaction mechanism, Int. J. Pharm., 17, 135-144.
104. Arien, A., Coigoux, C., Baquey, C., and Dupuy, B. (1993), Study of in vitro and in vivo stability of liposomes loading with calcitonin or indium in GIT, Life Sci., 53, 1279-1290.
105. D'Silva, J. B., and Notari, R. E. (1982), Drug stability in liposomal suspensions: Hydrolysis of indomethacin, cyclocytidine and p- nitrophenyl acetate, J. Pharm. Sci., 71, 1394-1398.
106. Kirby, C., Clarke, J., and Gregoriadis, G. (1980), Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro, Biochem. J., 186, 591-595.
107. Kirby, C., and Gregoriadis, G. (1980), The effect of the cholesterol content of small unillamellar liposomes on the fate of their lipid components in vivo, Life Sci., 27, 2223-2230.
108. Layton, D., and Trouet, A. (1980), A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leucemic mice, Eur. J. Cancer, 16, 945-951.
109. McCormack, B., and Gregoriadis, G. (1994), Drugs-in-cylcodextrins-liposomes: A novel concept in drug delivery, Int. J. Pharm., 112, 249-258.
110. McCormack, B., and Gregoriadis, G. (1996), Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-P-cyclodextrin-drug complexes after intravenous injection into rats: Implications in drug delivery, Biochim. Biophys. Acta, 1291, 237-244.
111. Fatouros, D. G., Hatzidimitirou, K., and Antimisiaris, S. G. (2001), Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: Comparison of membrane integrity and drug release, Eur. J. Pharm. Sci., 13, 287-296.
112. Grit, M., and Crommelin, D. J. A. (1993), Analysis and hydrolysis kinetics of phospho-lipids in aqueous liposome dispersions, in Gregoriadis G., Ed., Liposome Technology, Vol. I, CRC Press, Boca Raton, FL, pp. 455-487.
113. Grit, M., and Crommelin, D. J. A. (1993), Chemical stability of liposomes: Implications for their stability, Chem. Phys. Lipids, 64, 3-18.
114. Zuidam, N. J., and Crommelin, D. J. A. (1995), Chemical hydrolysis of phospholipids, J. Pharm. Sci., 84, 1113-1119.
115. Grit, M., de Smidt, J., Struijke, H. A., and Crommelin, D. J. A. (1989), Hydrolysis of natural soybean phosphatidylcholine in aqueous liposome dispersions, Int. J. Pharm., 50, 1-6.
116. Hunt, C. A., and Tsang, S. (1981), a-Tocopherol retards autoxidation and prolongs the shelf life of liposomes, Int. J. Pharm., 8, 101-110.
117. Fukuzawa, K., Chida, H., Akira,T., and Tsukatani, H. (1981), Autooxidative effect of at ocopherol incorporation into lecithin liposomes on ascorbic acid Fe+ +- induced lipid peroxidation, Arch. Biochem. Biophys., 206, 173-180.
118. Talsma, H., van Steenbergen, M. J., and Crommelin, D. J. A. (1992),The cryopreservation of liposomes. 2. Effect of particle size on crystallization behavior and marker retention, Cryobiology, 29, 80-86.
119. Talsma, H., van Steenbergen, M. J., and Crommelin, D. J. A. (1991),The cryopreservation of liposomes. 3. Almost complete retention of a water-soluble marker in small liposomes in a cryoprotectant containing dispersion after a freezing/thawing cycle, Int. J. Pharm., 77, 119-126.
120. Kristiansen, J. (1992), Leakage of a trapped fluorescent marker from liposomes: Effects of eutectic crystallization of NaCl and internal freezing, Cryobiology, 29, 575-584.
121. Crowe, L. M., and Crowe, J. H. (1988),Trehalose and dry dipalmitoloylphosphatidylcho-line revisited, Biochim. Biophys. Acta, 946, 193-201.
122. Crowe, J. H., Leslie, S. B., and Crowe, L. M. (1994), Is vitrification sufficient to preserve liposomes during freeze-drying? Cryobiology, 31, 355-366.
123. Piel, G., Piette, M., Barillaro, V., Castagne, D., Evrard, B., and Delattre, L. (2006), Beta-methasone-in-cyclodextrin-in-liposome: The effect of cyclodextrins on encapsulation efficiency and release kinetics, Int. J. Pharm., 312, 75-82.
124. Woodle, M. C., and Papahadjopoulos, D. (1989), Liposome preparation and size characterization, Meth. Enzym., 171, 193-217.
125. New, R. R. C., Ed. (1989), Liposomes. A PracticalApproach, IRL Press, Oxford. UK.
126. Bangham, A. D., and Horne, R. W. (1964), Negative staining of phospholipids and their structured modification by surface active agents as observed in the electron microscope. J. Mol. Biol., 8, 660-668.
127. Papahadjopoulos, D., and Watkins, J. C. (1967), Phospholipid model membrane 2: Permeability properties of hydrated liquid crystals, Biochim. Biophys. Acta, 135, 639-652.
128. Batzri, S., and Korn, E. D. (1973), Single bilayer vesicles prepared without sonication, Biochm. Biophys. Acta, 298, 1015-1019.
129. Deamer, D., and Bangham, A. D. (1976), Large volume liposomes by an ether vaporization method, Biochm. Biophys. Acta, 443, 629-634.
130. Barenholz, Y., Amselem, S., and Lichtenberg, D. (1979), A new method for preparation of phospholipid vesicles, FEBS Lett., 99, 210-214.
131. Mayhew, E., Lazo, R., Vail, W. J., King, J., and Green, A. M. (1984), Characterization of liposomes prepared using microfluidizer, Biochim. Biophys. Acta, 775,169-174.
132. Szoka, F. C., and Papahadjopoulos, D. (1978), Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation, Proc. Natl. Acad. Sci. USA, 75, 4194-4198.
133. Gregoriadis, G., Da Silva, H., and Florence A. T. (1990), A procedure for the efficient entrapment of drugs in dehydration- rehydration liposomes, Int. J. Pharm., 65, 235-242.
134. Zadi, B., and Gregoriadis, G. (2000), A novel method for high-yield entrapment of solutes into small liposomes, J. Lipos. Res., 10, 73-80.
135. Reeves, J. P., and Dowben R. M. (1969), Formation and properties of thin phospholipids vesicles, J. Cell. Phys., 73, 49-60.
136. Antimisiaris, S. G., Jayesekera, P., and Gregoriadis, G. (1993), Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant vesicles, J. Immunol. Methods, 166, 271-280.
137. Mimms, L. T., Zampighi, G., Nozaki, Y., Tanford, C., and Reynolds, J. A. (1981), Phos- pholipid vesicles formation and transmembrane protein incorporation using octyl glu-coside, Biochemistry, 20, 833-840.
138. Hauser, H., Brunner, J., and Skrabal, P. (1976), Single bilayer vesicles prepared without sonication, Biochim. Biophys. Acta, 455, 322-331.
139. Papahadjopoulos, D., Vail, W. J., Jacobson, K., and Poste, G. (1975), Cochleate lipid cylinders formation by fusion of unilamellar lipid vesicles, Biochim. Biophys. Acta, 394, 483-491.
140. Talsma, H., Van Steenbergen, M. J., Borchert, J. C. H., Crommelin, D. J. A. (1994), A novel technique for the one-step preparation of liposomes and nonionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: The "bubble" method, J. Pharm. Sci., 83, 276-280.
141. Avestin, Inc., Ottawa, Canada, http://www.avestin.com/products.html, accessed Jan. 1, 2004.
142. Mayer, L. D., Bally, M. B., and Cullis, P. R. (1990), Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients, Biochim. Biophys. Acta, 1025, 143-151.
143. Nichols, J. W., and Deamer, D. W. (1990), Catecholamine uptake and concentration of liposomes maintaining pH gradients, Biochim. Biophys. Acta, 455, 269-278.
144. Harrigan, P. R., Wong, K. F., Redelmeier, T. E., Wheller, J. J., and Cullis, P. R. (1993), Accumulation of doxorubicin and other lipophilic amines into LUVs in response to transmembrane pH gradient, Biochim. Biophys. Acta, 1149, 237-244.
145. Boman, N. L., Mayer, L. D., and Cullis, P. R. (1993), Optimization of the retention and properties of vincristine in liposomal systems, Biochim. Biophys. Acta, 1152, 253-258.
146. Gabizon, A., Shiota, R., and Papahadjopoulos. D. (1989), Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times, J. Nat. Can. Inst., 81,1484-1488.
147. Gabizon, A., Barenholz, Y., and Bialer, M. (1993), Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol derivatized phospholipid: Pharmacokinetic studies in rodents and dogs, Pharm. Res., 10, 703-708.
148. Cheung, B. C., Sun,T. H., Leenhouts, J. M., and Cullis, P. R. (1998), Loading of doxorubicin into liposomes by forming Mn-+-drug complexes, Biochim. Biophys. Acta, 1414, 205-216.
149. Abraham, S. A., Edwards, K., Karlsson, G., MacIntosh, S., Mayer, L. D., McKenzie, C, and Bally, M. B. (2002), Formation of transition metal-doxorubicin complexes inside liposomes, Biochim. Biophys. Acta, 1565, 41-54.
150. Nobs, L., Buchegger, F., Gurny, R., and Allemann, E. (2004), Current methods for attaching targeting ligands to liposomes and nanoparticles, J. Pharm. Sci., 93, 1980-1991.
151. Sapra, P., and Allen, T. M. (2003), Ligand-targeted liposomal anticancer drugs, Prog. Lipid Res., 42, 439-462.
152. Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P., and Huang, L. (1991), Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, Biochim. Biophys. Acta, 1062, 142-148.
153. Maruyama, K.,Takizawa,T.,Takahashi, N., Nagaike, K., and Iwatsuru, M. (1997), Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals, Adv. Drug Deliv. Rev., 24, 235-242.
154. Maruyama, K.,Takizawa,T., Yuda,T., Kennel, S. J., Huang, L., and Iwatsuru, M. (1995), Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies, Biochim. Biophys. Acta, 1234, 74-80.
155. Park, J. W., Benz, C. C., and Martin, F. J. (2004), Future directions of liposome- and immunoliposome-based cancer therapeutics, Semin. Oncol., 31(6 Suppl 13), 196-205.
156. Ishida, T., Iden, D. L., and Allen, T. M. (1999), A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs, FEBS Lett., 460, 129-133.
157. Park, C. G., Thiex, N. W., Lee, K. M., Szot, G. L., Bluestone, J. A., and Lee, K. D. (2003), Targeting and blocking B7 costimulatory molecules on antigen- presenting cells using CTLA4Ig-conjugated liposomes: In vitro characterization and in vivo factors affecting biodistribuiton, Pharm. Res., 20, 1239-1248.
158. Bartsch, M., Weeke-Klimp, A. H., Meijer, D. K. F., Scherphof, G. L., and Kamps, J. A. A. (2002), Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucle-otides targeted in vivo to hepatic endothelial cells, Pharm. Res., 19, 676-680.
159. Chekhonin, V. P., Zhirkov, Y. A., Gurina, O. I., Ryabukhin, I. A., Lebedev, S. V., Kashparov, I. A., and Dmitriyeva, T. B. (2005), PEGylated Immunoliposomes directed against brain astrocytes, Drug Deliv., 12, 1-6.
160. Brignole, C., Marimpietri, D., Gambini, C., Allen, T. M., Ponzoni, M., and Pastorino, F. (2003), Development of Fab' fragments of anti-GD2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma, Cancer Lett., 197, 199-204.
161. Demirovic, A. M., Marty, C., Console, S., Zeisberger, S. M., Ruch, C., Jaussi, R., Schwendener, R. A., and Ballmer-Hofer, K. (2005), Targeting human cancer cells with VEGF receptor- 2-directed liposomes, Oncol. Rept., 13, 319-324.
162. Voinea, M., Manduteanu, I., Dragomir, E., Capraru, M., and Simionescu, M. (2005), Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery, Pharm. Res., 22,1906-1917.
163. Park, J. W., Hong, K., Kiprotin, D. B., Meyer, O., Papahadjopoulos, D., and Benz, C. C. (1997), Anti-HER2 immunoliposomes for targeted therapy of human tumors, Cancer Lett., 118, 153-160.
164. Mercadal, M., Domingo, J. C., Petriz, J., Garcia, J., and de Madariaga, M. A. (1999), A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains, Biochim. Biophys. Acta, 1418, 232-238.
165. Longmuir, K. J., Robertson, R. T., Haynes, S. M., Baratta, J. L., and Waring, A. J. (2006), Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence, Pharm. Res., 23, 759-769.
166. Hansen, C. B., Kao, G.Y., Moase, E. H., Zalipsky, S., and Allen,T. M. (1995),Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures, Biochim. Biophys. Acta, 1239, 133-144.
167. Mamot, C., Ritschard, R., Kung, W., Park, J. W., Herrmann, R., and Rochlitz, C. F. (2006), EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells, J. Drug Targe., 14, 215-223.
168. Kallinteri, P., Papadimitriou, E., and Antimisiaris, S. G., (2001), Uptake of liposomes which incorporate a glycopeptide fraction of asialofetuin by HepG2 cells, J. Lipos. Res., 11, 175-193.
169. Fretz, M. M., Koning, G. A., Mastrobattista, E., Jiskoot, W., and Storm, G. (2004), OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis, Biochim. Biophys. Acta, 1665, 48-56.
170. Moreira, J. N., and Gaspar, R. (2004), Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer, Braz. J. Med. Biol. Res., 37, 1185-1192.
171. Martin, F. J., Hubbell, W. L., and Papahadjopoulos, D. (1981), Immunospecific targeting of liposomes to cells: A novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds, Biochemistry, 20,4229-1238.
172. Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L., Choi, S., DeChene, N. E., Doede, T., Huang, L., Pease, J. S., Shen, Z., Knox, S. J., and Cleland, J. L. (2004), Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier, Pharm. Res., 21, 1880-1885.
173. Anabousi, S., Bakowsky, U., Schneider, M., Huwer, H., Lehr, C. M., and Ehrhardt, C. (2006), In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer, Eur. J. Pharm. Sci., Jul 22, 29, 367374.
174. Lopez-Barcons, L. A., Polo, D., Llorens, A., Reig, F., and Fabra, A. (2005), Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferring liposomes: Effect of adriamycin ADR-to-lipid ratio, Oncol. Rept., 14, 1337-1343.
175. Afzelius, P., Demant, E. J. F., Hansen, G. H., and Jensen, P. B. (1989), Covalent modification of serum transferrin with phospholipids and incorporation into liposomal membranes, Biochim. Biophys. Acta, 979, 231-238.
176. Stavridis, J. C., Deliconstantinos, G.,Psallidopoulos,M. C.,Armenakas,N.A.,Hadjiminas, D. J., and Hadjiminas, J. (1986), Construction of transferrin-coated liposomes for on vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits, Exp. Cell Res., 164, 568-572.
177. Torchilin, V. P., Levchenko, T. S., Lukyanov, A. N., Khaw, B. A., Klibanov, A. L., Rammohan, R., Samokhin, G. P., and Whiteman, K. R. (2001), p- Nitrophenylcarbonyl -PEG-PE-liposomes: Fast and simple attachmentof specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p- nitrophenylcarbonyl groups, Biochim. Biophys. Acta, 1511, 397-411.
178. Savva, M., Duda, E., and Huang, L. (1999), A genetically modified recombinant tumor necrosis factor-a conjugated to the distal terminals of liposomal surface grafted poly-ethyleneglycol chains, Int. J. Pharm., 184, 45-51.
179. Ansell, S. M.,Tardi, P. G., and Buchkowsky, S. S. (1996), 3-(2-Pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates, Biocon-jugate Chem.,7,490-196.
180. Chua, M. M., Fan, S. T., and Karush, F. (1984), Attachment of immunoglobulin to lipo-somal membrane via protein carbohydrate, Biochim. Biophys. Acta, 800, 291-300.
181. Koning, G.A., Morselt, H.W.,Velinova, M. J., Donga, J., Gorter,A.,Allen,T. M., Zalipsky, S., Kamps, J. A., and Scherphof, G. L. (1999), Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer, Biochim. Biophys. Acta, 1420, 153-167.
182. Harding, J. A., Engbers, C. M., Newman, M. S., Goldstein, N. I., and Zalipsky, S. (1997), Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)- grafted immu-noliposomes, Biochim. Biophys. Acta, 1327, 181-192.
183. Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., and Torchilin, V. P. (2006), "SMART" drug delivery systems: Double-targeted pH-responsive. Pharmaceutical nanocarriers, Bioconjugate Chem., 17, 943-949.
184. Xiao, Z., McQuarrie, S. A., Suresh, M. R., Mercer, J. R., Gupta, S., and Miller, G. G. (2002), A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro, J. Biotechnol., 94,171-184.
185. Schnyder, A., Krahenbuhl, S., Torok, M., Drewe, J., and Huwyler, J. (2004), Targeting of skeletal muscle in vitro using biotinylated immunoliposomes, Biochem. J., 377, 61-67.
186. Allen,T. M., Mumbengegwi, D. R., and Charrois, J. R. (2005), Anti-CD19-targeted doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates, Clin. Cancer Res., 11, 3567-3573.
187. Gupta, B., Levchenko, T. S., Mongayt, D. A., and Torchilin, V. P. (2005), Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo, J. Drug Target., 13, 337-343.
188. Kawakami, S., Wong, J., Sato, A., Hattori, Y., Yamashita, F., and Hashida, M. (2000), Biodistribution characteristics of mannosylated, fucosylated, and galactosylated lipo-somes in mice, Biochim. Biophys. Acta, 1524, 258-265.
189. de Melo, A. L., Silva-Barcellos, N. M., Demicheli, C., and Frezard, F. (2003), Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes, Int. J. Pharm., 255, 227-230.
190. Chen, J-H., Ling, R., Yao, Q., Li, Y., Chen, T. Wang, Z., and Li, K-Z. (2005), Effect of small-sized liposomal adriamycin administered by various routes on a metastatic breast cancer model, Endocr.- Related Cancer, 12, 93-100.
191. Zhang, J. Q., Zhang, Z. R., Yang, Q. Y., Qin, S. R., and Qiu, X. L. (2005), Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo, Pharm. Res., 22, 573-583.
192. Wang, X. P., Yazawa, K., Templeton, N. S., Yang, J., Liu, S., Li, Z., Li, M., Yao, Q., Chen, C., and Brunicardi, F. C. (2005), Intravenous delivery of liposome- mediated nonviral DNA is less toxic than intraperitoneal delivery in mice, World J. Surg., 29, 339-343.
193. Kamps, J. A. A. M., and Scherphof, G. L. (2004), Biodistribution and uptake of liposomes in vivo, Methods Enzymol., 387, 257-266.
194. Moghimi, S. M., and Hunter, A. S. (2001), Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups, Pharm. Res., 18, 1-8.
195. Chiu, G. N., Bally, M. B., and Mayer, L. D. (2001), Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol), Biochim. Biophys. Acta, 1510, 56-69.
196. Harrington, K. J., Syrigos, K. N., and Vile, R. G. (2002), Liposomally targeted cytotoxic drugs for the treatment of cancer. J. Pharm. Pharmacol., 54, 1573-1600.
197. Forssen, E. A., Coulter, D. M., and Proffitt, R. T. (1992), Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumours, Cancer Res., 52, 3255-3261.
198. Forssen, E. A., Male-Brune, R., Adler-Moore, J. P., Lee, M. J., Schmidt, P. G., Krasieva,T. B., Shimizu, S., and Tromberg, B. J. (1996), Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue, Cancer Res., 56, 2066-2075.
199. Ogihara-Umeda, I., Sasaki,T., Kojima, S., and Nishigori, H. (1996), Optimal radiolabelled liposomes for tumour imaging, J. Nucl. Med., 37, 326-332.
200. Sadzuka, Y., and Hirota, S. (1998), Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Lett., 131, 163-170.
201. Turner, A. F., Presant, C. A., Proffitt, R. T., Williams, L. E., Winsor, D. W., and Werner, J. L. (1988), In-111-labelled liposomes: Dosimetry and tumour depiction, Rdiology, 166, 761-765.
202. Presant, C. A., Proffitt, R. T., Turner, A. F., Williams, L. E., Winsor, D., Werner, J. L., Kennedy, P., Wiseman, C., Gala, K., and McKenna, R. J. (1988), Successful imaging of human cancer with In- 111-labelled phospholipid vesicles, Cancer, 62, 905-911.
203. Presant, C. A., Blayney, D., Proffitt, R. D., Turner, A. F., Williams, L. E., Nadel, H. I., Kennedy, P., Wiseman, C., Gala, K., and Crossley, R. J. (1990), Preliminary report: Imaging of Kaposi sarcoma and lymphoma in AIDS with indium- 111-labelled liposomes, Lancet, 335, 1307-1309.
204. Kubo, A., Nakamura, K., Sammiya, T., Katayama, M., Hashimoto, T., Hashimoto, S., Kobayashi, H., and Teramoto, T. (1993), Indium-111-labelled liposomes: Dosimetry and tumour depiction in patients with cancer, Eur. J. Nucl. Med., 20, 107-113.
205. Khalifa, A., Dodds, D., Rampling, R., Paterson, J., and Murray, T., (1997), Liposomal distribution in malignant glioma: Possibilities for therapy, Nucl. Med. Commun., 18, 17-23.
206. Zucchetti, M., Boiardi, A., Silvani, A., Parisi, I., Piccolrovazzi, S., and D'Incalci, M. (1999), Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin, Cancer Chemother. Pharmacol., 44,173-176.
207. British National Formulary (BNF) Edition 51, 2006, Pharmaceutical Press, London.
208. http://www.gilead.com/pdf/daxpius.pdf#search='DaunoXome'. Gilead Sciences, Inc., 2007.
209. Shimizu, K.,Takada, M., Asai,T., Kuromi, K., Baba, K., and Oku, N. (2002), Cancer chemotherapy by liposomal 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103), a novel anticancer agent, Biol. Pharm. Bull., 25, 1385-1387.
210. Wu, P. C.,Tsai, Y. H., Liao, C. C., Chang, J. S., and Huang, Y. B. (2004),Tha characterization and biodistribution of cefoxitin- loaded liposomes, Int. J. Pharm., 271, 31-39.
211. Alberts, D. S., Markman, M., Armstrong, D., Rothenberg, M. L., Muggia, F., and Howell, S. B. (2002), Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! J. Clin. Oncol., 20, 3944.
212. Koga, S., Hamazoe, R., Maeta, M., Shimizu, N., Murakami, A., and Wakatsuki,T. (1988), Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyper-thermic peritoneal perfusion with mitomycin C, Cancer, 61, 232.
213. Speyer, J. L. (1985), The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies, Semin. Oncol., 12, 23.
214. Sadzuka, Y., Hirota, S., and Sonobe, T. (2000), Intraperitoneal administration of doxoru-bicin encapsulating liposomes against peritoneal dissemination, Toxicol. Lett., 116, 5159.
215. Sadzuka, Y., Nakai, S., Miyagishima, A., Nozawa, Y., and Hirota, S. (1997), Effects of administered route on tissue distribution and antitumour activity of polyethyleneglycol-coated liposomes containing adriamycin, Cancer Lett., 111, 77-86.
216. Marchettini,P.,Stuart,A.,Mohamed,F.,Yoo,D.,and Sugarbaker,P.H. (2002),Docetaxel: Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model, Cancer Chemother. Pharmacol., 49, 499-503.
217. Sadzuka, Y., Hirama, R., and Sonobe,T. (2002), Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy, Toxicol. Lett., 126, 83-90.
218. Di Stefano, A., Carafa, M., Sozio, P., Pinnen, F., Braghiroli, D., Orlando, G., Cannazza, G., Ricciutelli, M., Marianecci, C., and Santucci, E. (2004), Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations, J. Controlled Release, 99, 293-300.
219. Oussoren, C., and Storm, G. (2001), Liposomes to target the lymphatics by subcutaneous administration, Adv. Drug Deliv. Rev., 50, 143-156.
220. Gregoriadis, G., Bacon, A., Caparros-Wanderley, W., and McCormack, B. (2002), A role for liposomes in genetic vaccination, Vaccine 20, B1-B9.
221. Wu, M. S., Robbins, J. C., Bugianesi, R. L., Ponpipom, M. M., and Shen, T. Y. (1981), Modified in vivo behaviour of liposomes containing synthetic glycolipids, Biochim. Biophys. Acta, 674, 19-29.
222. Fujimoto, Y., Okuhata, Y.,Tyngi, S., Namba, Y., and Oku, N. (2000), Magnetic resonance lymphography of profunded lymphnodes with liposomal gadolinium- diethylenetriamine penta-acetic acid, Biol. Pharm. Bull., 23, 97-100.
223. Misselwitz, B., and Sachse, A. (1997), Interstitial MR lymphographyusing GD- carrying liposomes, Acta Radiol. Suppl., 412, 51-55.
224. Moll, K. P., Stober, R., Hermann, W., Borchert, H. H., and Utsumi, H. (2004), In vivo ESR studies on subcutaneously injected multilamellar liposomes in living mice, Pharm. Res., 21, 2017-2024.
225. Bacon, A., Caparros-Wanderley, W., Zadi, B., and Gregoriadis, G. (2002), Induction of a cytotoxic T lymphocyte (CTL) response to plasmid DNA delivered by Lipodine™, J. Liposome Res., 12, 173-183.
226. Perrie, Y., Barralet, J. E., McNeil, S., and Vangala, A. (2004), Surfactant vesicle- mediated delivery of DNA vaccines via the subcutaneous route, Int. J. Pharm., 284, 31-41.
227. Klibanov, A. L., Maruyama, K.,Torchilin, V. P., and Huang, L. (1990), Amphipathic poly-ethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268, 235-237.
228. Gabizon, A., and Papahadjopoulos, D. (1992),The role of surface charge and hydrophilic groups on liposome clearance in vivo, Biochim. Biophys. Acta, 1103, 94-100.
229. Ishida, O., Maruyama, K., Sasaki, K., and Iwatsuru, M. (1999), Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumour-bearing mice, Int. J. Pharm., 190, 49-56.
230. Levchenko, T. S., Rammohan, R., Lukyanov, A. N., Whiteman, K. R., and Torchilin, V. P. (2002), Liposome clearance in mice: The effect of a separate and combined presence of surface charge and polymer coating, Int. J. Pharm., 240, 95-102.
231. Lee, C. M., Choi, Y., Huh, E. J., Lee, K. Y., Song, H. C., Sun, M. J., Jeong, H. J., Cho, C. S., and Bom, H. S. (2005), Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: The effect of the extent of PEG ylation, Cancer Biother. Radiopharm., 20, 620-628.
232. Bradley, A. J., Devine, D. V., and Ansell, S. M. (1998), Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)- lipids, Arch. Biochem. Biophys., 357, 185-192.
233. Lu, W. L., Qi, X. R., Zhang, Q., Li, R.Y., Zhang, R. J., and Wei, S. L. (2004), A PEGylated liposomal platform: pharmacokinetics, pharmacodynamics and toxicity in mice using doxorubicin as a model drug, J. Pharmacol. Sci., 95, 381-389.
234. Ortho Biotech Products, L. P., http://www.doxil.com/common/prescribing_information/DOXIL/PDF/DOXIL_PI_Booklet.pdf#search='DOXIL', 2003-2007.
235. Blume, G., Cevc, G., Crommelin, M. D., Bakker-Woudenberg, I. A., Kluft, C., and Storm, G. (1993), Specific targeting with poly(ethylene glycol)-modified liposomes: Coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times, Biochim. Biophys. Acta, 1149, 180-184.
236. Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., and Zalipsky, S. (2003), In vivo fate of folate- targeted polyethylene-glycol liposomes in tumor- bearing mice, Clin. Cancer Res., 9, 6551-6559.
237. Maeda, N., Takeuchi, Y., Takada, M., Sadzuka, Y., Namba, Y., and Oku, N. (2004), Anti-neovascular therapy by use of tumour neovasculature- targeted long-circulating lipo-some, J. Controlled Release, 100, 41-52.
238. Syrigos, K. N., Vile, R. G., Peters, M., and Harrington, K. J. (2003), Biodistribution and pharmacokinetics of 111In- DTPA-labelled pegylated liposomes after intraperitoneal injection, Acta Oncol., 42, 147-153.
239. Cabanes, A., Even-Chen, S., Zimberoff, J., Barenholz, Y., Kedar, E., and Gabizon, A. (1999), Enhancement of antitumor activity of polyethylene glycol- coated liposomal doxorubicin with soluble and liposomal interleukin 2, Clini. Cancer Res., 5, 687-693.
240. Oussoren, C., Eling, W. M., Crommelin, D. J., Storm, G., and Zuidema, J. (1998), The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumour drugs, Biochim. Biophys. Acta, 1369, 159-172.
241. Patton, J. S., Fishburn, C. S., and Weers, J. G. (2004), The lungs as a portal of entry for systemic drug delivery, Proc. Am. Thorac. Soc., 1, 338-344.
242. Niven, R. W., and Scheier, H. (1990), Nebulization of liposomes. I. Effects of lipid composition, Pharm. Res., 7, 1127-1133.
243. Niven, R. W., Speer, M., and Scheier, H. (1991), Nebulization of liposomes. II. The effects of size and modeling of solute release profiles, Pharm. Res., 8, 217-221.
244. Niven, R. W., Carvajal, M. T., and Scheier, H. (1992), Nebulization of liposomes. III. Effect of operating conditions, Pharm. Res., 9, 515-520.
245. Taylor, K. M. G., Taylor, G., Kellaway, I. W., and Stevens, J. (1990), The stability of lipo-somes to nebulization, Inter. J. Pharm., 58, 57-61.
246. Schwarz, L. A., Johnson, J. L., Black, M., Cheng, S. H., Hogan, M. E., and Waldrep, J. C. (1996), Delivery of DNA-cationic liposome complexes by small particle aerosol, Hum. Gene Ther., 24, 35-36.
247. Eastman, S. J.,Tousignant, J. D., Lukason, M. J., Murray, H., Siegel, C. S., Constantino, P., Harris, D. J., Cheng, S. H., and Scheule, R. K. (1997), Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid: DNA complexes, Hum. Gen. Ther., 8, 313-322.
248. Gonzalez-Rothi, R. J., and Schreier, H. (1993), Pulmonary delivery of liposomes, J. Controlled Release, 5, 149-161.
249. Waldrep, J. C., Gilbert, B. E., Black, M., and Knight, V. (1997), Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate lipo-some aerosol, Chest, 111, 316-323.
250. Hochhaus, G., Gonzalez-Rothi, R. J., Lukyanov, A., Derendorf, H., and Dallas Costa, T. (1995), Assessment of glycocorticoid lung targeting by ex vivo receptor binding studies in rats, Pharm. Res., 12, 134-137.
251. Gonzalez-Rothi, R. J., Suarez, S., Hochhaus, G., Schreier, H., Lukyanov, A., Derendorf, H., and Dallas Costa, T. (1996), Pulmonary targeting of liposomal triamcinolone aceton- ide, Pharm. Res., 13, 1699-1703.
252. Schreier, H., McNicol, K. J., Ausborn, M., and Soucy, D. W., Derendorf, H., Stecenko, A. A., and Gonzalez-Rothi, R. J. (1992), Pulmonary delivery of amikacin liposomes and acute liposomes toxicity in the sheep, Int. J. Pharm., 87, 183-193.
253. Omri, A., Bealuc, C., Bouhajib, M., Montplaisir, S., Sharkawi, M., and Lagace, J. (1994), Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa, Antimicr. Agents Chemother., 38, 1090-1095.
254. Shek, P. N., Suntres, Z. E., and Brooks, J. I. (1994), Liposomes in pulmonary applications: Physicochemical considerations, pulmonary distribution and antioxidant delivery, J. Drug Targe., 2, 431-442.
255. Suntres, Z. E., and Shek, P. N. (1994), Incorporation of a-tocopherol in liposomes promotes the retention of liposome- encapsulated glutathione in the rat lung, J. Pharm. Pharmacol., 46, 23-28.
256. Suntres, Z. E., and Shek, P. N. (1995), Intratracheally administered liposomal alpha-tocopherol protects the lung against long-term toxic effects of paraquat, Biomed. Environ. Sci., 8, 289-300.
257. Walther, F. J., David-Cu, R., and Lopez, S. L. (1995), Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits, Am. J. Physiol., 269, L613-L617.
258. Vyas, S. P., Kannan, M. P., Jain, S., Mishra, V., and Singh, P. (2004), Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages, Int. J. Pharm., 269, 37-49.
259. Vyas, S. P., Quraishi, S., Gupta, S., and Jaganathan, K. S. (2005), Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages, Int. J. Pharm., 296, 12-25.
260. Doddoli, C., Ghez, O., Barlesi, F., D'Journo, B., Robitail, S., Thomas, P., and Clerc, T. (2005), In vitro and in vivo methotrexate disposition in alveolar macrophages: Comparison of pharmacokinetic parameters of two formulations, Int. J. Pharm., 297, 180-189.
261. Fidler, I. J., Raz, A., Fogler, W. E., Kirsh, R., Bugleski, P., and Poste, G. (1980), Design of liposomes to improve delivery of macrophage- augmenting agents to alveolar macro-phages, Cancer Res., 40, 4460-4466.
262. Juliano, R. L., and McCullough, H. N. (1980), Controlled delivery of an antitumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system, Am. Soc. Pharm. Exp. Ther., 214, 381-387.
263. McCullough, H. N., and Juliano, R. L. (1979), Organ-selective action of an antitumor drug: Pharmacologic studies of liposome- encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat, J. Natl. Cancer Inst., 63, 727-731.
264. Knight, V., Kleinerman, E. S., Waldrep, J. C., Giovanella, B. C., Gilbert, B. E., and Koshkina, N. V. (2000), 9 -Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice, Ann. N. Y. Acad. Sci., 922, 151-163.
265. Canonico, A. E., Conary, J. T, Meyrick, B. O., and Brigham, K. L. (1994), Aerosol and intravenous transfection of human a1-antitrypsin gene to lungs of rabbits, Am. J. Respir. Cell Mol. Biol., 10, 24-29.
266. Stribling, R., Brunette, E., Liggitt, D., Gaensler, K., and Debs, R. (1992), Aerosol gene delivery in vivo, Proc. Natl. Acad. Sci. USA, 89,11277-11281.
267. Rowland, R. N., and Woodley, J. F. (1980), The stability of liposomes in vitro to pH, bile salts and pancreatic lipase, Biochim. Biophys. Acta, 620, 400-409.
268. Nagata, M., Yotsuyanagi, T., and Ikeda, M. (1988), A two step model of disintegration kinetics of liposomes in bile salts, Chem. Pharm. Bull., 36, 1508-1513.
269. Quadachi, S., Paternostre, M., andre, C., Genin, I.,Thao,T. X., Puisieux, F., Devissaguet, J., and Barratt, G. (1998), Liposomal formulations for oral immunotherapy: In-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse, J. Drug Targe., 5, 365-378.
270. Freund, O. (2001), Biodistribution and gastrointestinal drug delivery of new lipidic multilamellar vesicles, Drug Deliv., 8, 239-244.
271. Mezei, M., and Gulasekharam, V. (1981), Liposomes: A selective drug delivery system for topical route of administration-gel dosage form, J. Pharm. Pharmacol., 34, 473-474.
272. Mezei, M., and Gulasekharam, V. (1980), Liposomes: A selective drug delivery system for topical route of administration. I-lotion dosage form, Life Sci., 26,1473-14777.
273. Honeywell-Nguyen, P. L., and Bouwstra, J. A. (2005), Vesicles as a tool for transdermal and dermal delivery, Drug Discovery Today: Technol., 2, 67-74.
274. Knepp, V. M., Hinz, R. S., Szoka, F. C., and Guy, R. H. (1988), Controlled drug release from a novel liposomal delivery system. I. Investigation of transdermal potential, J. Controlled Release, 5, 211-221.
275. Yu, H. Y., and Liao, H. M. (1996), Triamcinolone permeation from different liposome formulations through rat skin in vitro, Int. J. Pharm., 127, 1-7.
276. Fresta, M., and Puglisi, G. (1997), Corticosteroid dermal delivery with skin lipid lipo-somes, J. Controlled Release, 44, 141-151.
277. Liu, H., Pan, W. S.,Tang, R., and Luo, S. D. (2004),Topical delivery of acyclovir palmitate liposome formulations through rat skin in vitro, Pharmazie, 59, 203-206.
278. Egbaria, K., Ramanchandran, C., and Weiner, N. (1991), Topical application of liposo-mally entrapped cyclosporin evaluated by in vitro diffusion studies with human skin, Skin Pharmacol., 4, 21-28.
279. Manosroi, A., Konganeramit, L., and Manosroi, J. (2004), Stability and transdermal absorption of topical amphotericin B liposome formulations, Int. J. Pharm., 270, 279-286.
280. Aguillela, V., Kontturi, K., Murtomaki, L., and Ramirez, P. (1994), Estimation of the pore size and charge density in human cadaver skin, J. Controlled Release, 32, 249-257.
281. Cevc, G., Schatzlein, A., and Richardsen, H. (2002), Ultradeformable lipid vesicles can penetrate the skin and other semi- permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements, Biochim. Biophys. Acta, 564, 21-30.
282. Cevc, G. (1996), Transferosomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration and transdermal drug delivery, Crit. Rev. Ther. Drug Carrier Syst., 13, 257-388.
283. de Plessis, J., Ramachandran, C., Weiner, N., and Muller, D. G. (1994), The influence of particle size of liposomes on the deposition of the drug into skin, Int. J. Pharm., 103, 277-282.
284. Verma, D. D., Verma, S., Blume, G., and Fahr, A. (2003), Particle size of liposomes influences dermal delivery of substances into skin, Int. J. Pharm., 258,141-151.
285. Miyachi, Y., Imamura, S., and Niwas, Y. (1987), Decreased skin superoxide dismutase activity by a single exposure of ultraviolet radiation is reduced by liposomal superoxide dismutase pretreatment, J. Invest. Dermatal., 89, 111-112.
286. Short, S. M., Rubas, W., Paasch, B. D., Mrsny, R. (1995), Transport of biologically active interferon-gamma across human skin in vitro, Pharm. Res., 12, 1140-1145.
287. Cotsarelis, G. (2002), The hair follicle as a target for gene therapy, Ann. Dermatal Vene- reol., 129, 841-844.
288. Raghavachari, N., and Fahl, W. E. (2002), Targeted gene delivery to skin cells in vivo: A comparative study of liposomes and polymers as delivery vehicles, J. Pharm. Sci., 91, 615-622.
289. Balsari,A.L.,Morelli,D., Menard, S.,Veronesi,U., and Colnaghi,M.I. (1994), Protection against doxorubicin-i nduced alopecia in rats by liposome- entrapped monoclonal antibodies, Res. Commun., 8, 226-230.
290. Weiner, N., Williams, N., Birch, G., Ramachandran, R., Shipman, C., Jr., and Flynn, G. (1989), Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model, Antimicrob. Agents Chemoter., 33,1217-1221.
291. Godin, B., and Touitou, E. (2003), Ethosomes: New prospects in transdermal delivery, Crit. Rev. Ther. Drug Carrier Syst., 20, 63-102.
292. Kalia, Y. N., Naik, A., Garrison, J., Guy, R. H. (2004), Iontophoretic drug delivery, Adv. Drug Deliv. Rev., 56, 619-658.
293. Vulta,N. B.,Betageri, G.V.,and Banga,A.K. (1996),Transdermal iontophoretic delivery of enkephalin formulated in liposomes, J. Pharm. Sci., 85, 5-8.
294. Fang, J. Y., Sung, K. C., Lin, H. H., and Fang, C. L. (1999), Transdermal iontophoretic delivery of enoxacin from various liposome- encapsulated formulations, J. Controlled Release, 60, 1-10.
295. Essa, E. A., Bonner, M. C., and Barry, B. W. (2002), Iontophoretic estradiol skin delivery and tritium exchange in ultradeformable liposomes, Int. J. Pharm., 240, 55-66.
296. Essa, E. A., Bonner, M. C., and Barry, B. W. (2004), Electrically assisted skin delivery of liposomal estradiol; phospholipid as damage retardant, J. Controlled Release, 95, 535-546.
297. Conjeevaram, R., Chaturvedala, A., Betageri, G. V., Sunkara, G., and Banga, A. K. (2003), Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation, Pharm. Res., 9, 1496-1501.
298. Han, I., Kim, M., and Kim, J. (2004), Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis, Exp. Dermatol., 13, 86-92.
299. Wells, J. M., Li, L. H., Sen, A., Jahreis, G. P., and Hui, S. W. (2000), Electroporation-enhanced gene delivery in mammary tumors, Gene Ther., 7, 541-547.
300. Essa, E. A., Bonner, M. C., and Barry, B. W. (2003), Electroporation and ultradeformable liposomes; human skin barrier repair by phospholipids, J. Controlled Release, 92, 163-172.
301. Sen, A., Zhao, Y. L., and Hui, S. W. (2002), Saturated anionic phospholipids enhance transdermal transport by electroporation, Biophys. J., 83, 2064-2073.
302. Vyas, S. P., Singh, R., Asati, R. K. (1995), Liposomally encapsulated diclofenac for sono-phoresis induced systemic delivery, J. Microencapsul., 12, 149-154.
303. Ahmed, I., and Patton, T. F. (1987), Disposition of timolol and inulin in the rabbit eye following corneal versus noncorneal absorption, Int. J. Pharm., 38, 9-21.
304. Mishima, S., Gasset, A. Klyce, S. D., and Baum, J. L. (1966), Determination of tear volume and tear flow, Invest. Ophthalmol., 5, 264-276.
305. Ebrahim, S., Peyman, G., and Lee, P. J. (2005), Applications of liposomes in ophtalmology, Sur. Opthalmol., 50, 167-182.
306. Kaur, I. P., Garg, A., Singla, A. K., and Aggarwal, D. (2004), Vesicular systems in ocular drug delivery: An overview, Int. J. Pharm., 269, 1-14.
307. Zimmer, A. K., and Kreuter, J. (1991), Studies on the transport pathway of PBCA nanoparticles in ocular tissues, J. Microencapsul., 8, 497-504.
308. Marchal-Heussler, Sirbat D., and Hoffman, M. (1993), Poly-E-caprolactone nanocap-sules in carteolol ophthalmic delivery, Pharm. Res., 10, 386-390.
309. Calvo, P., Thomas, C., and Alonso, M. J. (1994), Study of the mechanism of interaction of poly-E,-caprolactone nanocapsules with the cornea by confocal laser scanning microscopy, Int. J. Pharm., 103, 283-291.
310. Schaeffer, H. E., Brietfelter, J. M., and Krohn, D. L. (1982), Lectin-mediated attachment of liposomes to cornea: Influence on transcorneal drug flux, Invest. Ophthalmol. Vis. Sci., 23, 530-533.
311. Dharma, S. K., Fishman, P. H., and Peyman, G. A. (1986), A preliminary study of corneal penetration of 125I, labelled iodoxuridine liposome, Acta Ophthalmol. (Copenh.), 64, 298-301.
312. Smolin, G., Okumoto, M., Feiler, S., and Condon, D. (1981), Iodoxuridine-liposome therapy for herpes simplex keratitis, Am. J. Ophthalmol., 91, 220-226.
313. Schaeffer, H. E., and Krohn, D. L. (1982), Liposomes in topical drug delivery, Invest. Ophthalmol. Vis. Sci., 22, 220-227.
314. Stratford, R. E. J., Yang, D. C., Redell, M. A., and Lee, V. H. L. (1983), Effects of topically applied liposomes and disposition of epinephrine and inulin in albino rabbit eye, Int. J. Pharm., 13, 263-272.
315. Stratford, R. E. J.,Yang, D. C., Redell, M. A., and Lee, V. H. L. (1983), Ocular distribution of liposome encapsulated epinephrine and inulin in the albino rabbit, Curr. Eye Res., 2, 377-386.
316. Lee, V. H. L., Takemoto, K. A., and Iimoto, D. S. (1984), Precorneal factors influencing the ocular distribution of topically applied liposomal inulin, Curr. Eye Res., 3, 585-591.
317. Angelucci, D. (2001, Nov.), New solutions for dry eye, EyeWorld, available: http://eye-world.org.pastissue.php.
318. Lin, H. H., Ko, S. M., Hsu, L. R., and Tsai, Y. H. (1996), The preparation of norfloxacin-l oaded liposomes and their in-vitro evaluation in pig's eye, J. Pharm. Pharmacol., 48, 801-805.
319. Frucht-Perry, J., Assil, K. K., Ziegler, E., et al. (1992), Fibrin-enmeshed tobramycin liposomes: Single application topical therapy of Pseudomonas keratitis, Cornea, 11, 393-397.
320. Assil, K. K., Frucht-Perry, J., Ziegler, E., et al. (1991), Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis, Invest. Ophthalmol. Vis. Sci., 32, 3216-3220.
321. Barza, M., Doft, B., and Lynch, E. (1993), Ocular penetration of ceftriaxone, ceftazidime, and vancomycin after subconjunctival injection in humans, Arch. Ophthalmol., 111, 492-494.
322. Pleyer, U., Grammar, J., Pleyer, J. H., et al. (1995), Amphotericin B-bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B, Ophthalmologe, 92, 469-475.
323. Law, S. L., Huang, K. J., and Chiang, C. H. (2000), Acyclovir- containing liposomes for potential ocular delivery. Corneal penetration and absorption, J. Controlled Release, 63(1-2), 135-140.
324. Fresta, M., Panico, A. M., Bucolo, C., et al. (1999), Characterization and in- vivo ocular absorption of liposome- encapsulated acyclovir, J. Pharm. Pharmacol., 51, 565-576.
325. Al-Muhammed, J., Ozer, A. Y., Ercan, M. T., and Hincal, A. A. (1996), In-vivo studies on dexamethasone sodium phosphate liposomes, J. Microencapsul., 13, 293-306.
326. Pleyer, U., Elkins, B., Ruckert, D., et al. (1994), Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields, Curr. Eye Res., 13,177-181.
327. Pleyer, U., Lutz, S., Jusko, W. J., et al. (1993), Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye, Invest. Ophthalmol. Vis. Sci., 34, 2737-2742 [erratum appears Invest. Ophthalmol. Vis. Sci., 34, 3481,1993].
328. Torres, P. F., Slegers, T. P., Peek, R., et al. (1999), Changes in cytokine mRNA levels in experimental corneal allografts after local clodronate-liposome treatment, Invest. Oph- thalmol. Vis. Sci., 40, 3194-3201.
329. Slegers, T. P., van Rooijen, N., van Rij, G., and van der Gaag, R. (2000), Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate lipo- somes, Curr. Eye Res., 20, 322-324.
330. Van der Veen, G., Broersma, L., Dijkstra, C. D., et al. (1994), Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate, Invest. Ophthalmol. Vis. Sci., 35, 3505-3515.
331. Van der Veen, G., Broersma, L., Van Rooijen, N., et al. (1998), Cytotoxic T lymphocytes and antibodies after orthotropic penetrating keratoplasty in rats treated with dichloromethylene diphosphonate encapsulated liposomes, Curr. Eye Res., 17, 1018-1026.
332. Lee, V. H., and Carson, L. W. (1986), Ocular disposition of inulin from single and multiple doses of positively charged multilamellar liposomes: Evidence for alterations in tear dynamics and ocular surface characteristics, J. Ocul. Pharmacol., 2, 353-364.
333. Elorza, B., Elorza, M. A., Sainz, M. C., and Chantres, J. R. (1993), Comparison of particle size and encapsulation parameters of three liposomal preparations, J. Microencapsul., 10, 237-248.
334. Felt, O., Furrer, P., Mayer, J. M., Plazonnet, B., Buri, P., and Gurny, R. (1999),Topical use of chitosan in ophthalmology: Tolerance assessment and evaluation of precorneal retention, Int. J. Pharm., 180, 185-193.
335. Felt, O., Baeyens, V., Zignani, M., Buri, P., and Gurny, R., (1999), Mucosal drug delivery, in Mathiowitz, E., Ed., The Encyclopedia of Controlled Drug Delivery,, Wiley, NewYork, pp. 605-626.
336. McCalden, T. A., and Levy, M. (1990), Retention of topical liposomal formulations on the cornea, Experientia, 46, 713-715.
337. Grass, G. M., and Robinson, J. R. (1988), Mechanisms of corneal drug penetration. I: In vivo and in vitro kinetics, J. Pharm. Sci., 77, 3-14.
338. Burrow, J., Tsibouklis, J., and Smart, J. D., (2002), Drug delivery to the eye, The Drug Delivery Company Report, p. 4.
339. Taniguchi, K., Yamamoto, Y., Itakura, K., Miichi, H., and Hayashi, S. (1988), Assessment of ocular irritability of liposome preparations, J. Pharmacobiodyn., 11, 607-611.
340. Barber, R. F., and Shek, P. N. (1990), Tear induced release of liposome entrapped agents, Int. J. Pharm., 60, 219-227.
341. Kaufman, H. E., Steinemann, T. L., Lehman, E.,Thompson, H. W., Varnell, E. D., Jacob-LaBarre, J. T., and Gebhardt, B. M. (1994), Collagen-based drug delivery and artificial tears, J. Ocul. Pharmacol., 10, 17-27.
342. Yerushalmi, N., and Margalit, R. (1994), Bioadhesive, collagen-modified liposomes: Molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers, Biochim. Biophys. Acta, 1189, 13-20.
343. Bochot, A., Fattal, E., Gulek, A., and Aonarraze, G. (1998), Liposome dispersed within thermosensitive gel. A new dosage form for ocular delivery of oligonucleotide, Pharm. Res., 15, 1364-1369.
344. Bochot, A., Couvreur, P., and Fattal, E. (2000), Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery, Prog. Retin. Eye Res., 19, 131-147.
345. Bochot, A., Fattal, E., Boutet, V., Deverre, J. R., Jeamy, J. C., Chacun, H., and Couvreur, P. (2002), Intravitreal delivery of oligonucleotides by sterically stabilized liposomes, Invest. Opthalmol. Vis. Sci., 43, 253-259.
346. Schmidt-Erfurth, U., Flotte, T. J., Gragoudas, E. S., et al. (1996), Benzoporphyrin -lipoprotein-mediated photodestruction of intraocular tumors, Exp. Eye Res., 62, 1-10.
347. Kawakami, S., Yamamura, K., Mukai, T., Nishida, K., Nakamura, J., Sakaeda, T., Nakashima, M., and Sasaki, H. (2001), Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes, J. Pharm. Pharmacol., 53, 157-161.
348. Harris, A. S., Svensson, E., Wagner, Z. G., Lethagen, S., and Nilsson, I. M. (1988), Effect of viscosity on particle-size, deposition, and clearance of nasal delivery systems containing desmopressin, J. Pharm. Sci., 77, 405-408.
349. Vyas, S. P., Goswami, S. K., and Singh, R. (1995), Liposomes based nasal delivery system of nifedipine-development ad characterization, Int. J. Pharm., 118, 23-30.
350. Shahiwala A, and Misra, A. (2004), Nasal delivery of levonorgestrel for contraception: An experimental study in rats, Fertil. Steril. 81(Suppl. 1), 893-898.
351. Kuper, H., Adami, H. O., and Trichopoulos, D. (2000), Infection as a major preventable cause of human cancer, J. Intern. Med., 248, 171-183.
352. Alpar, H. O., Somavarapu, S., Atuah, K. N., and Bramwell, V. W. (2005), Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery, Adv. Drug Deliv. Rev., 57, 411-430.
353. De Haan, A., Renegar, K. B., Small, P. A., Wilschut, J., (1995), Vaccine, 13, 613-616.
354. Wang, D., Christopher, M. E., Nagata, L. P., Zabielski, M. A., Li, H., Wong, J. P., and Samuel, J. (2004), Intranasal immunization with liposome- encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses, J. Clin. Virol., 31 (Suppl. 1), 99-106.
355. Tafaghodi, M., Jaafari, M.-R., and Abolghasem, S., and Tabassi, S. (2006), Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG- ODN, Eur. J. Pharm. Biopharm., 64,138-145.
356. de Jonge, M. I., Hamstra, H. J., Jiskoot, W., Roholl, P., Williams, N. A., Dankert, J., van Alphen, L., and Van der Ley, P. (2004), Intranasal immunisation of mice with lipo-somes containing recombinant meningococcal OpaB and OpaJ proteins, Vaccine, 22, 4021-4028.
357. Sloat, B. R., and Zhengrong, C. (2006), Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in lipo-some-protamine-DNA particles, Pharm. Res., 23, 262-269.
358. Paveli, Z., Skalko-Basnet, N., and Schubert, R. (2001), Liposomal gels for vaginal drug delivery, Int. J. Pharm., 219, 139-149.
359. Paveli, Z., Skalko-Basnet, N., and Jalsenjak, I. (2005), Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis, Int. J. Pharm., 301, 140-148.
360. Paveli, Z., Skalko-Basnet, N., Filipovi-Gri, J., Martinac, A., and Jalsenjak, I. (2005), Development and in vitro evaluation of a liposomal vaginal delivery system for acyclo-vir, J. Controlled Release, 106, 34-43.
361. Zhang, Y., Cristofaro, P., Silbermann, R., Pusch, O., Boden, D., Konkin, T., Hovanesian, V., Monfils, P. R., Resnick, M., Moss S. F., and Ramratnam, B. (2006), Engineering mucosal RNA interference in vivo, Mol. Ther., 14, 336-342.
362. Hartikka, J., Bozoukova, V., Ferrari, M., Sukhu, L., Enas, J., Sawdey, M., et al. (2001), Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens, Vaccine, 19, 1911-1923.
363. Lochera, C. P., Witta, S. A., Ashlocka, B. M., Polacinob, P., Hub, S. L., Shiboskic, S., Schmidtb, A. M., Agyb, M. B., anderson, D. M., Stapransd, S. I., Megedee, J., and Levy, J. A. (2004), Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection, Vaccine, 22, 2261-2272.
364. Davidson, R. N., Croft, S. L., Scott, A., Maini, M., Moody, A. H., and Bryceson, A. D. (1991), Liposomal amphotericin B in drug-resistant visceral leishmaniasis, Lancet, 337, 1061-1062.
365. Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., et al. (1994), Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome), Invest. New Drugs, 12,103-110.
366. Gabizon, A., Peretz, T., Sulkes, A., Amselem, S., Ben-Yosef, R., Ben-Baruch, N., et al. (1989), Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study, Eur. J. Cancer Clin. Oncol., 25, 1795-1803.
367. Donald, P. R., Sirgel, F. A., Venter, A., Smit, E., Parkin, D. P., VandeWal, B. W., et al. (2001), The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis, J. Antimicrob. Chemother., 48, 877-880.
368. Kadry, A. A., Al-Suwayeh, S. A., Abd-Allah, A. R., and Bayomi, M. A. (2004),Treatment of experimental osteomyelitis by liposomal antibiotics, J. Antimicrob. Chemother., 54, 1103-1108.
369. Nishiyama, N., and Kataoka, K. (2006), Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery, Pharmacol. Therap., 112, 630-648.
370. Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H., Zuhowski, E. G., Pluim, D., et al. (2004), Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI- 077 B103) in a preclinical tumor model of melanoma, Cancer Chemother. Pharmacol., 53, 329-336.
371. Proulx, M. E., Desormeaux, A., Marquis, J. F., Olivier, M., and Bergeron, M. G. (2001), Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camp-tothecin, Antimicrob. Agents Chemother., 45, 2623-2627.
372. Giles, F. J.,Tallman, M. S., Garcia-Manero, G., Cortes, J. E.,Thomas, D. A., Wierda, W. G., et al. (2004), Phase I and pharmacokinetic study of a low-clearance, unilamellar liposo-mal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia, Cancer, 100, 1449-1458.
373. Verschraegen, C. F., Gilbert, B. E., Loyer, E., Huaringa, A., Walsh, G., Newman, R. A., et al. (2004), Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies, Clin. Cancer Res., 10, 2319-2326.
374. Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., et al. (2004), Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A phase I study, Clin. Cancer Res., 10, 7244-7251.
375. Chien, P. Y., Wang, J., Carbonaro, D., Lei, S., Miller, B., Sheikh, S., et al. (2004), Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo, Cancer Gene Ther., 12, 321-328.
376. Asano, T., and Kleinerman, E. S. (1993), Liposome-encapsulated MTP-PE: A novel biologic agent for cancer therapy, J. Immunother., 14, 286-292.
377. Dagar, S., Krishnadas, A., Rubinstein, I., Blend, M. J., and Onyuksel, H. (2003), VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies, J. Controlled Release, 91, 123-133.
378. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., et al. (2002), Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery, Clin. Cancer Res., 8, 1172-1181.
379. Pakunlu, R. I., Wang, Y.,Tsao,W., Pozharov,V., Cook,T. J., and Minko,T. (2004), Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system, Cancer Res., 64, 6214-6224.
380. Pardridge, W. M. (1996), Vector- mediated drug delivery to the brain, Adv. Drug Deliv., 36, 299-321.
381. Huwyler, J., Wu, D., and Pardridge, W. M. (1996), Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA, 93,14164-14169.
382. Huwyler, J., Yang, J., and Pardridge, W. M. (1997),Targeted delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat, J. Pharmacol. Exp. Ther., 282, 1541-1546.
383. Schnyder, A., Krahenbuhl, S., Drewe, J., and Huwyler, J. (2005),Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects, J. Drug Targeting., 13, 325-335.
384. Xie, Y., Ye, L., Zhang, X., Cui, W., Lou, J., Nagai, T., and Hou, X. (2005), Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies, J. Controlled Release, 105, 106-119.
385. Brignole, C., Marimpietri, D., Pagnan, G., Di Paolo, D., Zancolli, M., Pistoia, V., Ponzoni, M., and Pastorino, F. (2005), Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti,GD2 immunoliposome: Immune cell,mediated antitumor activities, Cancer Lett., 228,181-186.
386. Siegal, T., Horowitz, A., and Gabizon, A. (1995), Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy, J. Neurosurg., 83,1029-1037.
387. Sharma, U. S., Sharma, A., Chau, R. I., and Straubinger, R. M. (1997), Liposome-mediated therapy of intracranial brain tumors in a rat model, Pharm. Res., 14, 992-998.
388. Aoki, H., Kakinuma, K., Morita, K., Kato, M., Uzuka, T., Igor, G., Takahashi, H., and Tanaka, R. (2004), Therapeutic efficacy of targeting chemotherapy using local hyper-thermia and thermosensitive liposome: Evaluation of drug distribution in a rat glioma model, Int. J. Hypertherm., 20, 595-605.
389. Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., and Karkavitsas, N. (2000), High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumors, Br. J. Cancer, 83, 1281-1286.
390. Arnold, R. D., Mager, D. E., Slack, J. E., and Straubinger, R. M. (2005), Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model, Clin. Cancer Res., 11, 8856-8865.
391. Marina, N. M., Cochrane, D., Harney, E., Zomorodi, K., Blaney, S., Winick, N., Bernstein, M., and Link, M. P. (2002), Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study, Clin. Cancer Res., 8, 413-418.
392. Caraglia, M., Addeo, R., Costanzo, R., Montella, L., Faiola, V., Marra, M., Abruzzesse, A., Palmieri, G., Budillon, A., Grillone, F., Venuta, S., Tagliaferri, P., and Del Prete, S. (2006), Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumors, Cancer Chemother. Pharmacol., 57, 34-39.
393. Fiorillo, A., Maggi, G., Greco, N., Migliorati, R., D'Amico, A., Del Basso De Caro, M., Sabbatino, M. S., and Buffardi,F. (2004), Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors, J. Neuro-Oncol., 66, 179-185.
394. Barth, R. F., Coderre, J. A., Graca, M., Vicente, H., and Blue,T. E. (2005), Boron neutron capture therapy of cancer: Current status and future prospects, Clin. Cancer Res., 11, 3987-4002.
395. Hawthorne, M. F., Feakes, D. A., and Shelly, K. (1996), Recent results with liposomes as boron delivery vehicles from boron neutron capture therapy, in Mishima, Y., Ed., Cancer Neutron Capture Therapy, Plenum, New York, pp 27-36.
396. Feakes, D. A., Waller, R. C., Hathaway, D. K., and Morton, V. S. (1999), Synthesis and in vivo murine evaluation of Na4[1-(1'-B10H9)-6-SHB10H8] as a potential agent for boron neutron capture therapy, Proc. Natl. Acad. Sci. USA, 96, 6406-6410.
397. Carlsson, J., Kullberg, E. B., Capala, J., Sjoberg, S., Edwards, K., and Gedda, L. (2003), Ligand liposomes and boron neutron capture theory, J. Neuro-Oncol., 62, 47-59.
398. Barth, R. F., Yang, W., Adams, D. M., Rotaru, J. H., Shukla, S., Sekido, M., Tjarks, W., Fenstermaker, R. A., Ciesielski, M., Nawrocky, M. M., and Coderre, J. A. (2002), Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas, Cancer Res., 62, 3159-3166.
399. Wikstrand, C. J., Cokgor, I., Sampson, J. H., and Bigner, D. D. (1999), Monoclonal antibody therapy of human gliomas: Current status and future approaches, Cancer Metastasis Rev., 18, 451-464.
400. Hermanson, M., Funa, K., Koopmann, J., Maintz, D., Waha, A., Westermark, B., Heldin, C. H., Wiestler, O. D., Louis, D. N., von Deimling, A., and Nister, M. (1996), Association of loss of heterozygosity on chromosome 17p with high platelet derived growth factor alpha receptor expression in human malignant gliomas, Cancer Res., 56, 164-171.
401. Akabani, G., Cokgor, I., Coleman, R. E., Gonzalez Trotter, D., Wong, T. Z., Friedman, H. S., Friedman, A. H., Garcia-Turner, A., Herndon, J. E., DeLong, D., McLendon, R. E., Zhao, X. G., Pegram, C. N., Provenzale, J. M., Bigner, D. D., and Zalutsky, M. R. (2000), Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine- 131-labeled anti-tenascin monoclonal antibody 81C6 therapy, Int. J. Radiat. Oncol. Biol. Phys., 46, 947-995.
402. Yoshida, J., and Mizuno, M. (2003), Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma, J. Neuro-Oncol., 65, 261-267.
403. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. R., Ringold, G. M., and Danielson, M. (1987), Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA, 84, 7413-7414.
404. Zhang, Y., Jeong, Lee, H., Boado, R. J., and Pardridge, W. M. (2002), Receptro-mediated delivery of an antisense gene to human brain cancer cells, J. Gene Med., 4, 183-194.
405. Zhang, Y., Zhu, C., and Pardridge, W. M. (2002), Antisense gene therapy of brain cancer with an artificial virus gene delivery system, Mol. Ther., 6, 67-72.
406. Zhang, Y., Zhang,Y. F., Bryant, J., Charles, A., Boado, R. J., and Pardridge, W. M. (2004), Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer, Clin. Cancer Res., 10, 3667-3677.
407. Zerrouqi, A., Rixe, O., Ghoumari, A. M., Yarovoi, S. V., Mouawad, R., Khayat, D., and Soubrane, C. (1996), Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: Improvement of cell sensitization to ganciclovir, Cancer Gene Ther., 3, 385-392.
408. Voges, J., Weber, F., Reszka, R., Sturm, V., Jacobs, A., Heiss, W. D., Wiestler, O., and Kapp, J. F. (2002), Clinical protocol; Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme, Hum. Gene Ther., 13, 675-685.
409. Mizuno, M., and Yoshida, J. (1998), Improvement of transduction efficiency of recombi-nant adeno-associated virus vector by entrapment in multilamellar liposomes, Jpn. J. Cancer Res., 89, 352-354.
410. Huynh, G. H., Deen, D. F., and Szoka, F. C., Jr. (2006), Barriers to carrier mediated drug and gene delivery to brain tumours, J. Controlled Release, 110, 236-259.
411. Bomgaars, L., Geyer, J. R., Franklin, J., Dahl, G., Park, J., Winick, N. J., Klenke, R., Berg, S. L., and Blaney, S. M. (2004), Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis, J. Clin. Oncol., 22, 3916-3921.
412. Glantz, M., LaFollette, S., Jaeckle, K., Shapiro,W., Swinnen, L., Rozental, J., Phuphanich, S., Rogers, L., Gutheil, J., Batchelor, T., Lyter, D., Chamberlain, M., Maria, B., Schiffer, C., Bashir, R., Thomas, D., Cowens, W., and Howell, S. B. (1999), A randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis, J. Clin. Oncol. 17, 3110-3116.
413. MakCay, A. J., Deen, D. F., and Szoka, F. C., Jr. (2005), Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating, Brain Res., 1035,139-153.
414. Polfliet, M. M., Goede, P. H., van Kesteren-Hendrikx, E. M., van Rooijen, N., Dijkstra, C. D., and van De Berg, T. K. (2001), Amethod for the selective depletion of perivascular and meningeal macrophages in the central nervous system, J. Neuroimmunol., 116, 188-195.
415. Mamot, C., Nguyen, J. B., Pourdehnad, M., Hadaczek, P., Saito, R., Bringas, J. R., Drum-mond, D. C., Park, J.W., and Bankiewicz, K. S. (2004), Extensive distribution of liposomes in rodent brains and brain tumors following convection- enhanced delivery, J. Neuro-Oncol., 68, 1-9.
416. Saito, R., Bringas, J. R., McKnight,T. R., Wendland, M. F., Mamot, C., Drummond, D. C, Kiprotin, D. B., Park, J. W., Berger, M. S., and Bankiewicz, K. S. (2004), Distribution of liposomes into brain and rat brain tumor models by convection- enhanced delivery monitored with magnetic resonance imaging, Cancer Res., 64, 2572-2579.
417. Saito, R., Krauze, M. T., Bringas, J. R., Noble, C., McKnight,T. R., Jackson, P., Wendland, M. F., Mamot, C., Drummond, D. C., Kiprotin, D. B., Hong, K., Berger, M. S., Park, J. W., and Bankiewicz, K. S. (2005), Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhaced delivery in the primate brain, Exp. Neurol., 196, 381-389.
418. Groothuis, D. R. (2000), The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery, Neuro-Oncol., 2, 45-59.
419. Imaginis Corp. (The Women 's Health Resource), http://www.imaginis.com/breasthealth/treatment.asp, 1997-2007.
420. Hofheinz, R. D., Gnad-Vogt, S. U., Beyer, U., and Hochhaus, A. (2005), Liposomal encapsulated anti- cancer drugs, Anti-Cancer Drugs, 16, 691-707.
421. Gradishar, W. J. (2005),The future of breast cancer:The role of prognostic factors, Breast Cancer Res. Treat., 89, S17-S26.
422. Batist, G., Ramakrishnan, G., and Rao, C. S. (2001), Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multi-center trial of metastatic breast cancer, J. Clin. Oncol., 19, 1444-1454.
423. Paridaens, R., Van Aaelst, F., and Georgoulias, V. (2003), A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first line chemotherapy for metastatic breast cancer, Ann. Oncol., 14,433-140.
424. Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., and Lee, L. W. (2004), Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first line therapy for metastatic breast cancer, Ann. Oncol., 15, 1527-1534.
425. Mrozek, E., Rhoades, C. A., Allen, J., Hade, E. M., and Shapiro, C. L. (2005), Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients, Ann. Oncol., 16, 1087-1093.
426. Schmid, P., Krocker, J., Jehn, C., Michniewicz, K., Lehenbauer-Dehm, S., Eggemann, H., Heilmann, V., Kummel, S., Schulz, C. O., Dieing, A., Wischnewsky, M. B., Hauptmann, S., Elling, D., Possinger, K., and Flath, B. (2005), Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial, Ann. Oncol., 16, 1624-1631.
427. Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J. M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., Minckwitz, G., Henderson, G., Mellars, L., Alland, L., and Tendler, G. (2004), Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane- refractory advanced breast cancer. J. Clin. Oncol., 22, 3893-3901.
428. Vorobiof, D. A., Rapoport, B. L., Chasen, M. R., Slabber, C., McMichael, G., Eek, R., and Mohammed, C. (2004), First in line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metstatic breast cancer: A multicentre phase II study, Breast, 13, 219-226.
429. Overmoyer, B., Silvermann, P. Holder, L. W., Tripathy, D., and Henderson, I. C. (2005), Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer, Clin. Breast Cancer, 6,150-157.
430. Coleman, R. E., Biganzoli, L., Canney, P., Dirix, L., Mauriac, L., Chollet, P., Batter, V., Ngalula-Kabanga, E., Dittrich, C., and Piccart, M. (2006), A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993), Eur. J. Cancer, 42, 882-887.
431. Stover, T. C., Sharma, A., Robertson, G. P., and Kester, M. (2005), Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma, Clin. Cancer Ther., 11, 3465-3474.
432. Swenson, S., Costa, F., Minea, R., Sherwin, R. P., Ernst, W., Fujii, G., Yang, D., and Markland, F. S., Jr. (2004), Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression, Mol. Cancer Ther., 3, 499-511.
433. Nagami, H., Matsumoto, Y., and Ueoka, R. (2006), Induction of apoptosis by hybrid liposomes for human breast tumor calls along with activation caspases, Biol. Pharm. Bull., 29, 380-381.
434. Frenkel, V., Etherington, A., Greene, M., Quijano, J., Xie, J., Hunter, F., Dromi, S., and Li, K. C. P. (2006), Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: Investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure, Acad. Radiol., 13, 467-479.
435. Mukherjee, A., Prassad, T. K., Rao, N. M., and Banerjee, R. (2005), Haloperidol -associated stealth liposomes, J. Biol. Chem., 280,16(22), 1561-1562.
436. Seki, M., Iwakawa, J., Cheng, H., and Cheng, P. W. (2002), p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy, Hum. Gene Ther., 13, 761-773.
437. Basma, H., El-Refaey, H., Sgagias, M. K., Cowan, K. H., Luo, X., and Cheng, P. W. (2005), Bcl-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53, J. Biom. Sci., 12, 999-1011.
438. Meidan, V. M., Glezer, J., Salomon, S., Sidi, Y., Barenholz, Y., Cohen, J. S., and Lilling G. (2006), Specific lipoplex-mediated antisense against bcl-2 in breast cancer cells: A comparison between different formulations, J. Liposome Res., 16, 27-13.
439. Gradishar, W. J. (2005),The future of breast cancer:The role of prognostic factors, Breast Cancer Res. Treat., 89, S17-S26.
440. NetDoctor.co.uk, http://www.netdoctor.co.uk/diseases/facts/lungcancer.htm, 2007.
441. http://www.merck.de/servlet/PB/menu/1508710/index.html.
442. Leighl, N., Burkes, R. L., Dancey, J. E., Lopez, P. G., Higgins, B. P., Walde, P. L. D., Rudinskas, L. C., Rahim, Y. H., Rodgers, A., Pond, G. R., and Shepherd, F. A. (2003), A phase I study of pegylated liposomal doxorubicin (Caelyx™) in combination with cyclophosphamide and vincristine as second-fine treatment of patients with small-cell lung cancer, Clin. Lung Cancer, 5, 107-112.
443. Peer, D., and Margalit, R. (2004), Tumor- targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models, Neoplasia, 6, 343-353.
444. Ito, I., Ji, L., Tanaka, F., Saito, Y., Gopalan, B., Branch, C. D., Xu, K., Atkinson, E. N., Bekele, B. N., Stephens, L. C., Minna, J. D., Roth, J. A., and Ramesh, R. (2004), Liposomal vector mediated delivery of the 3p FUS1 gene demonstrate potent antitumor activity against human lung cancer in vivo, Cancer Gene Ther., 11, 733-739.
445. Li, W., Ishida, T., Okada, N., and Kiwada, H. (2005), Increased gene expression by cat-ionic liposomes (TFL-3) in lung metastases following intravenous injection, Biol. Pharm. Bull., 28, 701-706.
446. Kawakami, A., Suzuki, S., Yamashita, F., and Hashida, M. (2006), Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes, J. Controlled Release, 110, 514-521.
447. Remaut, K., Lucas, B., Braeckmans, K., Sanders, N. N., Demeester, J., and De Smedt, S. C. (2006), Delivery of phosphodiester oligonucleotides: Can DOTAP/DOPE liposomes do the trick? Biochemistry, 45,1755-1764.
448. American Cancer Society, Inc., http://www.cancer.org, 2007.
449. Johnston, S. (2004), Ovarian cancer: Review of the national institute for clinical excellence (NICE) guidance recommendations, Cancer Inv., 22, 730-742.
450. Rose, P. (2005), Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer, Oncologist, 10, 205-214.
451. Tambaro, R., Greggi, S., Iaffaioli, R. V., Rossi, A., Pisano, C., Manzione, L., Ferrari, E., Di Maio, M., Iodice, F., Casella, G., Laurelli, G., and Pignata, S. (2003), An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer, Ann. Oncol., 14, 1406-1411.
452. Katsaros, D., Oletti, M.V., Rigault de la Longrais, I. A., Ferrero, A., Celano, A., Fracchioli, S., Donadio, M., Passera, R., Cattel, L., and Bumma, C. (2005), Clinical and pharmaco-kinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma, Ann Oncol., 16, 300-306.
453. Gordon, A. N., Fleagle, J. T., Guthrie, D., et al. (2001), Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topo-tecan, J. Clin. Oncol., 19, 3312-3322.
454. Verhaar-Langereis, M., Karakus, A., van Eijkeren, M., Voest, E., and Witteveen, E. (2006), Phase II study of the combination of pegylated liposomal doxorubicin and topo-tecan in platinum-resistant ovarian cancer, Int. J. Gynecol. Cancer, 16, 65-70.
455. Seiden, M. V., Muggia, F., Astrow, A., Matulonis, U., Campos, S., Roche, M., Sivret, J., Rusk, J., and Barrett, E. (2004), A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer, Gynecol. Oncol., 93, 229-232.
456. Calvert, A. H., Grimshaw, R., Poole, C., Dark, G., Swnerton, K., Gore, M., et al. (2002), Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): An NCIC CTG study, Proc. Am. Soc. Clin. Oncol., 21, 208a.
457. National Cancer Institute, U.S. National Institutes of Health, http://www.cancer.gov/search/ResultsClinicalTrials, 2007.
458. Gallo, D., Fruscella, E., Ferlini, C., Apollonio, P., Mancuso, S., and Scambia, G. (2006), Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP), Int. J. Gynecol. Cancer, 16, 222-230.
459. Anderson, K., Lawson, K. A., Simmons-Menchaca, M., Sun, L., SAnders, B. G., and Kline, K. (2004), a-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis, Exp. Biol. Med., 229,1169-1176.
460. Turk, M. J., Waters, D. J., and Low, P. S. (2004), Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma, Cancer Lett., 213,165-172.
461. Kim, C. K., Choi, E. J., Choi, S. H., Park, J. S., Haider, K. H., and Ahn, W. S. (2003), Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC, Gynecol. Oncol., 90, 265-272.
462. Landen, C. N., Jr., Chavez-Reyes, A., Bucana, C., SchmAndt, R., Deavers, M. T., Lopez -Berestein, G., and Sood, A. K. (2005), Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery, Cancer Res., 65, 6910-6918.